HHSN261201500003I; HHSN26100079; 400.001.0079.0001; NCI OD-frederick; royalty; B539 phase 2 refurbishment; 9/24/2018-9/11/2022
Ended Awarded Last action
- Contract number
- 75N91018F00079
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $58,133,183
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $58,133,183.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $58,133,183 |
Show all 11
About this award
This is a $58,133,183.00 delivery order awarded by the Department of Health and Human Services' National Institutes of Health, National Cancer Institute to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for a B539 PHASE 2 REFURBISHMENT project with a period of performance from September 24, 2018 to September 11, 2022, with a completion date of August 25, 2023. It is a cost-plus-fixed-fee contract type. Leidos Biomedical Research provides a range of research, development, and production services to federal agencies, with a focus on supporting biomedical research programs at organizations like the NIH. This order is associated with Leidos Biomedical Research's role as a Federally Funded Research and Development Center (FFRDC) for the National Cancer Institute, under a $6.6 billion, five-year indefinite delivery contract running from 2019-2024. The contract does not have a set-aside designation.
Quick answers
Who was awarded contract 75N91018F00079?
75N91018F00079 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2018.
How much is contract 75N91018F00079 worth?
The government has obligated $58,133,183 on 75N91018F00079.
Is contract 75N91018F00079 an order under another contract?
Yes. 75N91018F00079 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract 75N91018F00079 competed?
The extent of competition for 75N91018F00079 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award